As expected, the Darmstadt-based MerckDE0006599905 group is swallowing the US cancer specialist Springworks Therapeutics US85205L1070.

Merck is paying $47 per Springworks share. This values ​​the company at €3 billion, as Merck announced on Monday. The acquisition will be financed with existing cash and new debt. The purchase is expected to close in the second half of 2025. Springworks shareholders and regulatory approvals must be obtained beforehand. For Merck, this is the largest acquisition in years. Last week, the DAX-listed company reported "advanced discussions."

Springworks will contribute directly to the Merck Group's sales, the statement added. Merck expects a positive impact on earnings per share in fiscal year 2027. Furthermore, with the acquisition, Merck is expanding both its Healthcare division and its presence in the United States. Following this acquisition, Merck remains in a position to handle further larger transactions, said CEO Belén Garijo in a statement: "Beyond this intended transaction, we will continue to explore opportunities for suitable acquisitions in our three complementary business sectors."